<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>ContentLora: Cancer immunotherapy</title><description>New and updated Cancer immunotherapy pages on ContentLora.</description><link>https://contentlora.com/</link><language>en</language><atom:link href="https://contentlora.com/topics/cancer-immunotherapy/feed.xml" rel="self" type="application/rss+xml"/><item><title>Antibody-drug conjugates (ADCs)</title><link>https://contentlora.com/wiki/antibody-drug-conjugates/</link><guid isPermaLink="true">https://contentlora.com/wiki/antibody-drug-conjugates/</guid><description>Antibody-drug conjugates link an antibody to a toxic payload. Not immunotherapy themselves, they are increasingly paired with checkpoint inhibitors.</description><pubDate>Sat, 10 Oct 2026 00:00:00 GMT</pubDate><category>Wiki</category><category>cancer-immunotherapy</category><category>health</category><category>life-sciences</category></item><item><title>Bispecific antibodies and T-cell engagers</title><link>https://contentlora.com/wiki/bispecific-t-cell-engagers/</link><guid isPermaLink="true">https://contentlora.com/wiki/bispecific-t-cell-engagers/</guid><description>Bispecific antibodies bind two targets at once, either linking T cells to tumours or pairing PD-1 with VEGF blockade. Approvals and 2026 trial results.</description><pubDate>Sat, 10 Oct 2026 00:00:00 GMT</pubDate><category>Wiki</category><category>cancer-immunotherapy</category><category>health</category><category>life-sciences</category></item><item><title>CAR-T cell therapy</title><link>https://contentlora.com/wiki/car-t-cell-therapy/</link><guid isPermaLink="true">https://contentlora.com/wiki/car-t-cell-therapy/</guid><description>CAR-T cell therapy: engineered T cells approved for blood cancers since 2017. Approvals, safety rules, the 2026 solid-tumour first and what comes next.</description><pubDate>Sat, 10 Oct 2026 00:00:00 GMT</pubDate><category>Wiki</category><category>cancer-immunotherapy</category><category>health</category><category>life-sciences</category></item><item><title>Immune checkpoint inhibitors</title><link>https://contentlora.com/wiki/immune-checkpoint-inhibitors/</link><guid isPermaLink="true">https://contentlora.com/wiki/immune-checkpoint-inhibitors/</guid><description>Checkpoint inhibitors such as pembrolizumab release immune brakes like PD-1 and CTLA-4. How they work, who responds, side effects and 2026 approvals.</description><pubDate>Sat, 10 Oct 2026 00:00:00 GMT</pubDate><category>Wiki</category><category>cancer-immunotherapy</category><category>health</category><category>life-sciences</category></item><item><title>In vivo CAR-T</title><link>https://contentlora.com/wiki/in-vivo-car-t/</link><guid isPermaLink="true">https://contentlora.com/wiki/in-vivo-car-t/</guid><description>In vivo CAR-T aims to make CAR-T cells inside the body with one infusion, skipping cell manufacturing. Early 2025-2026 myeloma data, safety and limits.</description><pubDate>Sat, 10 Oct 2026 00:00:00 GMT</pubDate><category>Wiki</category><category>cancer-immunotherapy</category><category>health</category><category>life-sciences</category></item><item><title>Personalised mRNA neoantigen vaccines</title><link>https://contentlora.com/wiki/personalized-neoantigen-vaccines/</link><guid isPermaLink="true">https://contentlora.com/wiki/personalized-neoantigen-vaccines/</guid><description>Individualised mRNA cancer vaccines such as intismeran autogene and autogene cevumeran: how they work, the 2026 phase 3 win and the setbacks.</description><pubDate>Sat, 10 Oct 2026 00:00:00 GMT</pubDate><category>Wiki</category><category>cancer-immunotherapy</category><category>health</category><category>life-sciences</category></item><item><title>Tumour-infiltrating lymphocyte (TIL) therapy</title><link>https://contentlora.com/wiki/tumor-infiltrating-lymphocyte-therapy/</link><guid isPermaLink="true">https://contentlora.com/wiki/tumor-infiltrating-lymphocyte-therapy/</guid><description>TIL therapy grows a patient&apos;s own tumour-derived T cells and infuses them back. The 2024 FDA approval of lifileucel, results and open questions.</description><pubDate>Sat, 10 Oct 2026 00:00:00 GMT</pubDate><category>Wiki</category><category>cancer-immunotherapy</category><category>health</category><category>life-sciences</category></item><item><title>Cancer immunotherapy tracker: approvals and trial results</title><link>https://contentlora.com/events/cancer-immunotherapy-tracker/</link><guid isPermaLink="true">https://contentlora.com/events/cancer-immunotherapy-tracker/</guid><description>A dated, sourced timeline of cancer immunotherapy milestones from 2024 to October 2026: approvals, phase 3 readouts, safety actions and setbacks.</description><pubDate>Sat, 10 Oct 2026 00:00:00 GMT</pubDate><category>Developing</category><category>cancer-immunotherapy</category><category>health</category><category>life-sciences</category></item><item><title>Can immunotherapy crack solid tumours? The 2026 debate</title><link>https://contentlora.com/analysis/solid-tumor-immunotherapy-debate/</link><guid isPermaLink="true">https://contentlora.com/analysis/solid-tumor-immunotherapy-debate/</guid><description>Solid tumours are the main frontier of cancer immunotherapy. What 2025-2026 trials show, where they fall short, and the competing readings.</description><pubDate>Sat, 10 Oct 2026 00:00:00 GMT</pubDate><category>Analysis</category><category>cancer-immunotherapy</category><category>health</category><category>life-sciences</category></item><item><title>Cancer immunotherapy in 2026: a crash course</title><link>https://contentlora.com/explain/cancer-immunotherapy/</link><guid isPermaLink="true">https://contentlora.com/explain/cancer-immunotherapy/</guid><description>A sourced crash course on cancer immunotherapy in 2026: checkpoint inhibitors, CAR-T, bispecifics, mRNA cancer vaccines and the solid-tumour frontier.</description><pubDate>Sat, 10 Oct 2026 00:00:00 GMT</pubDate><category>Explainer</category><category>cancer-immunotherapy</category><category>health</category><category>life-sciences</category></item><item><title>How cancer vaccines work, from shared antigens to personalised mRNA</title><link>https://contentlora.com/explain/how-cancer-vaccines-work/</link><guid isPermaLink="true">https://contentlora.com/explain/how-cancer-vaccines-work/</guid><description>How therapeutic cancer vaccines differ from preventive ones, how personalised mRNA neoantigen vaccines are made, and what trials show as of 2026.</description><pubDate>Sat, 10 Oct 2026 00:00:00 GMT</pubDate><category>Explainer</category><category>cancer-immunotherapy</category><category>health</category><category>life-sciences</category></item><item><title>How CAR-T cell therapy works</title><link>https://contentlora.com/explain/how-car-t-cell-therapy-works/</link><guid isPermaLink="true">https://contentlora.com/explain/how-car-t-cell-therapy-works/</guid><description>How CAR-T cells are made from a patient&apos;s own T cells, why they cause cytokine release syndrome, and why solid tumours are harder, at two reading levels.</description><pubDate>Sat, 10 Oct 2026 00:00:00 GMT</pubDate><category>Explainer</category><category>cancer-immunotherapy</category><category>health</category><category>life-sciences</category></item><item><title>How the immune system fights cancer, and how tumours escape</title><link>https://contentlora.com/explain/how-the-immune-system-fights-cancer/</link><guid isPermaLink="true">https://contentlora.com/explain/how-the-immune-system-fights-cancer/</guid><description>How T cells recognise cancer, how tumours hide or switch immune cells off, and how immunotherapies try to reverse that, at beginner and expert level.</description><pubDate>Sat, 10 Oct 2026 00:00:00 GMT</pubDate><category>Explainer</category><category>cancer-immunotherapy</category><category>health</category><category>life-sciences</category></item></channel></rss>